Howard Levine has been litigating some of the most complex and valuable biotechnology and pharmaceutical litigations over the past 25 years. He has been at the forefront of the development of the law in these practice areas, including precedent concerning the written description requirement under 35 U.S.C. § 112.
Howard has conducted all aspects of pre-trial, trial, and post-trial proceedings, including appeals to the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court.
His practice concentrates on patent litigation before the federal district courts and the U.S. Court of Appeals for the Federal Circuit, primarily in the areas of biotechnology and pharmaceuticals. Howard has extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA).
Howard has represented both pharmaceutical and biotechnology companies in technologies ranging from the inhibition of NF-B to genetically engineered corn. He was involved in litigations between Eli Lilly, Genentech, and the Regents of the University of California regarding human insulin, the first biotechnology product to be marketed.
Some of the products involved in the litigations for which Howard served as counsel include, Humulin®, Humatrope®, Zantac®, Paxil®, Evista®, Xigris®, Cymbalta®, Gemzar®, Differin®, Savella®, Bunavail®, Belbuca® and most recently, Howard defended Forests patent Saphris® sublingual product, delivering the opening and taking the key witnesses at trial concerning the nonobviousness of Forest’s patent.
- Georgetown University Law Center J.D., cum laude, 1993
- Duke University B.A., Biology, cum laude, 1990
- District of Columbia
- New York
- U.S. Court of Appeals, Federal Circuit
- Supreme Court of the United States
- U.S. Patent and Trademark Office
Professional Activities :
- American Intellectual Property Law Association
- New York Intellectual Property Law Association
- District of Columbia Bar (Intellectual Property Section)
Rate : $$$$